OCUL
Ocular Therapeutix Inc
NASDAQ: OCUL · HEALTHCARE · BIOTECHNOLOGY
$9.21
-1.18% today
Updated 2026-04-29
Market cap
$2.00B
P/E ratio
—
P/S ratio
38.59x
EPS (TTM)
$-1.42
Dividend yield
—
52W range
$6 – $16
Volume
4.9M
Ocular Therapeutix Inc (OCUL) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.29M | $19.15M | $78.19M | $110.31M | $74.94M | $55.43M | $73.04M | $78.74M | $261.86M | $204.89M | $149.29M | $252.06M | $457.94M |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $24.26M | $18.01M | $76.18M | $106.98M | $69.90M | $43.34M | $56.19M | $60.17M | $246.16M | $191.30M | $129.63M | $232.24M | $440.99M |
| Total liabilities | $71.90M | $78.62M | $19.50M | $20.72M | $22.93M | $29.28M | $37.17M | $82.37M | $185.77M | $116.89M | $113.91M | $160.93M | $142.59M |
| Current liabilities | $3.48M | $3.34M | $5.87M | $5.38M | $8.30M | $13.43M | $9.16M | $12.03M | $26.66M | $26.34M | $31.39M | $34.90M | $41.35M |
| Long-term debt | $2.26M | $651000.00 | $13.51M | $15.27M | $14.09M | $12.47M | $24.79M | $49.31M | $41.24M | $51.44M | $54.01M | $74.92M | $68.50M |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-47.46M | $-60.78M | $-89.43M | $-129.18M | $-173.88M | $-237.26M | $-297.24M | $-383.62M | $-539.25M | $-545.80M | $-616.84M | $-697.58M | $-891.08M |
| Accounts receivable | $45000.00 | $269000.00 | $329000.00 | $193000.00 | $250000.00 | $226000.00 | $201000.00 | $2.55M | $12.25M | $21.14M | $21.32M | $26.18M | $32.39M |
| Inventory | — | — | $133000.00 | $134000.00 | $113000.00 | $122000.00 | $217000.00 | $954000.00 | $1.20M | $1.25M | $1.97M | $2.31M | $3.04M |
| Goodwill | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |